ORYZON announces FDA Approval of IND for ETHERAL, a Phase IIa trial of the epigenetic drug Vafidemstat in Patients with mild to moderate Alzheimer’s disease
MADRID, SPAIN and CAMBRIDGE MA.
• Recruitment is ongoing in Europe
• The European and US Study will recruit a total of 150 patients
Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that Oryzon has received confirmation from the U.S. Food and Drug Administration (FDA) that its Investigational New Drug application (IND) is now open for vafidemstat (ORY-2001) for the treatment of mild to moderate Alzheimer’s disease (AD) patients. Oryzon submitted its IND for this Phase IIa clinical trial of vafidemstat in patients with Alzheimer’s disease to the FDA on February 6, 2019.